NCT06051786View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions
Allergic Rhinitis
Interventions
DRUG

azelastine/fluticasone 137/50 mcg nasal spray

AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).

DRUG

Dymista™

Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).

Trial Locations (5)

100

National Taiwan University Hospital, Taipei

106

Cathay General Hospital, Taipei

112

Taipei Veterans General Hospital, Taipei

407

Taichung Veterans General Hospital, Taichung

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

Synmosa Biopharma Corp.

INDUSTRY

NCT06051786 - A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis | Biotech Hunter | Biotech Hunter